Effect of Conversion From Ciclosporin to Tacrolimus on Endothelial Progenitor Cells in Stable Long-Term Kidney Transplant Recipients

BACKGROUNDEndothelial progenitor cell (EPC) counts are proposed surrogate markers for vascular function and cardiovascular risk. The effect of tacrolimus (TAC) on EPC is unknown. METHODSIn this randomized controlled trial, we assigned 148 stable long-term kidney transplant recipients (KTR) to maintaining ciclosporin (CSA) or to commencing TAC-based immunosuppression at a 2:1 ratio. EPC counts (CD34/KDR) after 24 months were defined as primary endpoint. RESULTSThe intent-to-treat analysis included 141 KTR (estimated glomerular filtration rate, 46.7 [40.1–61.8] mL/min per 1.73 m). Median (interquartile range [IQR]) EPC counts at baseline and month 24 were 6 (2–9) and 3 (1–9) cells and 4 (2–8) and 2 (0–5) cells per 5×10 mononuclear cells in CSA and TAC, respectively. Median (IQR) circulating angiogenic cells at baseline and month 24 were 28 (10.7–57) and 44.33 (14.6–59.8) cells and 22 (10.8–41) and 21 (9.7–49.5) cells per high-power field in CSA and TAC, respectively. Median (IQR) endothelial cell colony-forming units count per well at baseline and month 24 were 10.5 (3.3–34.3) and 4.38 (1.7–26.5) in CSA and significantly declined from 9.31 (1.8–29.3) to 4.13 (1.1–9.5) in TAC (P=0.003). There were no cardiovascular events in either group. CONCLUSIONAlthough late conversion from CSA to TAC appears safe in KTR, conversion to TAC has no favorable effect on EPC. Low EPC levels are associated with a higher risk of subsequent cardiovascular events and are therefore of prognostic value. Their trend to decline over time deserves further examination.